Peripheral blood lymphocytes immunophenotype and serum concentration of soluble HLA class I in burn patients

Lebedev, M.Ju; Krizhanova, M.A; Vilkov, S.A; Шолкина, М. Н.; Vyasmina, E.S; Baryshnikov, AY; Novikov, V. V.

doi:10.1016/s0305-4179(02)00245-0

Cited by 11 publications

(5 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In determining the content of sHLA-I molecules, we used monoclonal antibodies ICO-53 and ICO-216 conjugated with horseradish peroxidase. The concentration of sHLA-II molecules was examined by using monoclonal antibodies ICO-1 and goat polyclonal antibodies against HLA-II molecules conjugated with horseradish peroxidase as described in [25]. The results were expressed in conventional units (U/ml).…”

Section: Methodsmentioning

confidence: 99%

Soluble HLA-I and HLA-II Molecules Are Potential Prognostic Markers of Progression of Systemic and Local Inflammation in Patients with COPD

Kubysheva

Soodaeva²,

Novikov

et al. 2018

Disease Markers

View full text Add to dashboard Cite

Soluble molecules of the major histocompatibility complex play an important role in the development of various immune-mediated diseases. However, there is not much information on the participation of these proteins in the pathogenesis of chronic obstructive pulmonary disease (COPD). The aim of our work was to determine the content of soluble molecules of the major histocompatibility complex of classes I and II (sHLA-I and sHLA-II) in the exhaled breath condensate (EBC) and in the blood serum in patients with moderate to severe COPD during the exacerbation and stable phase. We investigated 105 patients (male) with COPD aged 46–67 and 21 healthy nonsmoking volunteers (male) comparable in age. The content of sHLA-I and sHLA-II molecules was studied using ELISA. We found an increase in the level of sHLA-I and sHLA-II molecules in EBC, as well as an enhancement in the serum content of sHLA-II in all the examined COPD patients compared to healthy nonsmoking volunteers. The revealed negative correlation between the serum concentration of sHLA-II and values of FEV1 and FEV1/FVC in all examined patients with COPD gives a possibility to consider the content of these proteins as an additional systemic marker of disease severity. The maximum endobronchial and serum concentrations of sHLA-I and sHLA-II were detected in patients with severe COPD during the exacerbation. The negative associations between the content of these molecules in EBC and serum and the parameters of lung function in patients with severe COPD were established. These findings suggest a pathogenetic role of sHLA-I and sHLA-II molecules in the mechanisms of the development and progression of local and systemic inflammation in COPD.

show abstract

Section: Methodsmentioning

confidence: 99%

Soluble HLA-I and HLA-II Molecules Are Potential Prognostic Markers of Progression of Systemic and Local Inflammation in Patients with COPD

Kubysheva

Soodaeva²,

Novikov

et al. 2018

Disease Markers

View full text Add to dashboard Cite

show abstract

“…The levels of soluble CD25, CD38, CD8, and sHLA-I-CD8 molecules in the serum and EBC were determined by enzyme-linked immunosorbent assay (ELISA) using an ELISA reader (Multiskan MS, Labsystems, Finland) at a wavelength of 405 nm. In determining the content of soluble CD25, CD38, and CD8 molecules, we used goat polyclonal antibodies against human leukocyte cell antigen and mouse monoclonal antibodies ICO-105, ICO-20, and ICO-31 against human CD25, CD38, and CD8 molecules conjugated with horseradish peroxidase as described in [ 28 – 31 ].…”

Section: Methodsmentioning

confidence: 99%

Relationship of the Content of Systemic and Endobronchial Soluble Molecules of CD25, CD38, CD8, and HLA-I-CD8 and Lung Function Parameters in COPD Patients

et al. 2017

View full text Add to dashboard Cite

The definition of new markers of local and systemic inflammation of chronic obstructive pulmonary disease (COPD) is one of the priority directions in the study of pathogenesis and diagnostic methods improvement for this disease. We investigated 91 patients with COPD and 21 healthy nonsmokers. The levels of soluble CD25, CD38, CD8, and HLA-I-CD8 molecules in the blood serum and exhaled breath condensate (EBC) in moderate-to-severe COPD patients during exacerbation and stable phase were studied. An unidirectional change in the content of sCD25, sCD38, and sCD8 molecules with increasing severity of COPD was detected. The correlations between the parameters of lung function and sCD8, sCD25, and sHLA-I-CD8 levels in the blood serum and EBC were discovered in patients with severe COPD. The findings suggest a pathogenetic role of the investigated soluble molecules of the COPD development and allow considering the content of sCD8, sCD25, and sHLA-I-CD8 molecules as additional novel systemic and endobronchial markers of the progression of chronic inflammation of this disease.

show abstract

“…For example, shedding of membrane differentiation molecules from immune cell membranes is a common posttranslational protein modification in normal conditions and inflammation. As a result, the level of soluble differentiation molecules and histocompatibility molecules is elevated in biological fluids [22][23][24]. With regard to allergies, the most known soluble protein biomarkers are IgE and IgG antibodies specific for the disease-causing allergens, cytokines, enzymes, and other proteins, such as soluble differentiation molecules of the immune cells, i.e., membrane protein markers.…”

Section: Protein Biomarkers and Their Role In Asthmamentioning

confidence: 99%

Protein Biomarkers in Asthma

Karaulov

Garib

et al. 2018

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Asthma is a chronic disabling respiratory disease that can be triggered by a variety of factors, including allergens, respiratory infections, psychological factors, occupational agents, exercise, atmospheric pollutants, and drugs. The asthma syndrome has been treated for decades according to a “one-fits-all” treatment strategy based on bronchodilators and steroids. With the availability of new forms of treatment targeting the different pathomechanisms of the asthma syndrome, such as anti-immunoglobulin E and cytokine-targeting therapies, the interest in biomarkers that can dis criminate different forms of asthma according to their pathomechanisms has increased. This review attempts to provide an overview of protein biomarkers in asthma and how they might be used to discriminate different forms of asthma that may respond positively to sophisticated new targeted therapies.

show abstract

Peripheral blood lymphocytes immunophenotype and serum concentration of soluble HLA class I in burn patients

Cited by 11 publications

References 17 publications

Soluble HLA-I and HLA-II Molecules Are Potential Prognostic Markers of Progression of Systemic and Local Inflammation in Patients with COPD

Soluble HLA-I and HLA-II Molecules Are Potential Prognostic Markers of Progression of Systemic and Local Inflammation in Patients with COPD

Relationship of the Content of Systemic and Endobronchial Soluble Molecules of CD25, CD38, CD8, and HLA-I-CD8 and Lung Function Parameters in COPD Patients

Protein Biomarkers in Asthma

Contact Info

Product

Resources

About